Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Breaking up is hard to do.

Van Epps HA, Senter PD.

Nat Chem Biol. 2019 Oct;15(10):934-935. doi: 10.1038/s41589-019-0351-1. No abstract available.

PMID:
31451759
2.

A coiled-coil masking domain for selective activation of therapeutic antibodies.

Trang VH, Zhang X, Yumul RC, Zeng W, Stone IJ, Wo SW, Dominguez MM, Cochran JH, Simmons JK, Ryan MC, Lyon RP, Senter PD, Levengood MR.

Nat Biotechnol. 2019 Jul;37(7):761-765. doi: 10.1038/s41587-019-0135-x. Epub 2019 May 27.

PMID:
31133742
3.

Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug Conjugates.

Neumann CS, Olivas KC, Anderson ME, Cochran JH, Jin S, Li F, Loftus LV, Meyer DW, Neale J, Nix JC, Pittman PG, Simmons JK, Ulrich ML, Waight AB, Wong A, Zaval MC, Zeng W, Lyon RP, Senter PD.

Mol Cancer Ther. 2018 Dec;17(12):2633-2642. doi: 10.1158/1535-7163.MCT-18-0643. Epub 2018 Sep 21.

PMID:
30242091
4.

Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins.

Lau UY, Benoit LT, Stevens NS, Emmerton KK, Zaval M, Cochran JH, Senter PD.

Mol Pharm. 2018 Sep 4;15(9):4063-4072. doi: 10.1021/acs.molpharmaceut.8b00477. Epub 2018 Aug 14.

PMID:
30067902
5.

Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models.

Burke PJ, Hamilton JZ, Pires TA, Lai HWH, Leiske CI, Emmerton KK, Waight AB, Senter PD, Lyon RP, Jeffrey SC.

Mol Cancer Ther. 2018 Aug;17(8):1752-1760. doi: 10.1158/1535-7163.MCT-18-0073. Epub 2018 Jun 4.

6.

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.

Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.

Mol Cancer Ther. 2018 Feb;17(2):554-564. doi: 10.1158/1535-7163.MCT-17-0742. Epub 2017 Nov 15.

7.

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.

Burke PJ, Hamilton JZ, Jeffrey SC, Hunter JH, Doronina SO, Okeley NM, Miyamoto JB, Anderson ME, Stone IJ, Ulrich ML, Simmons JK, McKinney EE, Senter PD, Lyon RP.

Mol Cancer Ther. 2017 Jan;16(1):116-123. doi: 10.1158/1535-7163.MCT-16-0343. Epub 2016 Nov 9.

8.

Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates.

Levengood MR, Zhang X, Hunter JH, Emmerton KK, Miyamoto JB, Lewis TS, Senter PD.

Angew Chem Int Ed Engl. 2017 Jan 16;56(3):733-737. doi: 10.1002/anie.201608292. Epub 2016 Dec 14.

9.

Cutting back on the carbs.

Trang VH, Senter PD.

Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10228-30. doi: 10.1073/pnas.1612432113. Epub 2016 Sep 1. No abstract available.

10.

The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates.

Kolakowski RV, Haelsig KT, Emmerton KK, Leiske CI, Miyamoto JB, Cochran JH, Lyon RP, Senter PD, Jeffrey SC.

Angew Chem Int Ed Engl. 2016 Jul 4;55(28):7948-51. doi: 10.1002/anie.201601506. Epub 2016 May 20.

PMID:
27198854
11.

Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.

Burke PJ, Hamilton JZ, Pires TA, Setter JR, Hunter JH, Cochran JH, Waight AB, Gordon KA, Toki BE, Emmerton KK, Zeng W, Stone IJ, Senter PD, Lyon RP, Jeffrey SC.

Mol Cancer Ther. 2016 May;15(5):938-45. doi: 10.1158/1535-7163.MCT-16-0038. Epub 2016 Mar 4.

12.

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index.

Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD.

Nat Biotechnol. 2015 Jul;33(7):733-5. doi: 10.1038/nbt.3212. Epub 2015 Jun 15.

PMID:
26076429
13.

The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.

Belcher JD, Chen C, Nguyen J, Abdulla F, Nguyen P, Nguyen M, Okeley NM, Benjamin DR, Senter PD, Vercellotti GM.

PLoS One. 2015 Feb 23;10(2):e0117772. doi: 10.1371/journal.pone.0117772. eCollection 2015.

14.

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates.

Lyon RP, Setter JR, Bovee TD, Doronina SO, Hunter JH, Anderson ME, Balasubramanian CL, Duniho SM, Leiske CI, Li F, Senter PD.

Nat Biotechnol. 2014 Oct;32(10):1059-62. doi: 10.1038/nbt.2968. Epub 2014 Sep 7.

PMID:
25194818
15.

A previously undescribed tubulin binder.

Field JJ, Waight AB, Senter PD.

Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13684-5. doi: 10.1073/pnas.1414572111. Epub 2014 Sep 3. No abstract available.

16.

Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer.

Drachman JG, Senter PD.

Hematology Am Soc Hematol Educ Program. 2013;2013:306-10. doi: 10.1182/asheducation-2013.1.306. Review.

PMID:
24319196
17.

Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.

Okeley NM, Alley SC, Senter PD.

Hematol Oncol Clin North Am. 2014 Feb;28(1):13-25. doi: 10.1016/j.hoc.2013.10.009. Review.

PMID:
24287064
18.

Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation.

Okeley NM, Toki BE, Zhang X, Jeffrey SC, Burke PJ, Alley SC, Senter PD.

Bioconjug Chem. 2013 Oct 16;24(10):1650-5. doi: 10.1021/bc4002695. Epub 2013 Sep 19.

PMID:
24050213
19.

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, Okeley NM, Sanderson RJ, Stone IJ, Zeng W, Gregson SJ, Masterson L, Tiberghien AC, Howard PW, Thurston DE, Law CL, Senter PD.

Bioconjug Chem. 2013 Jul 17;24(7):1256-63. doi: 10.1021/bc400217g. Epub 2013 Jun 28.

PMID:
23808985
20.

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, Zeng W, Harrington KH, Klussman K, Westendorf L, Meyer D, Bernstein ID, Senter PD, Benjamin DR, Drachman JG, McEarchern JA.

Blood. 2013 Aug 22;122(8):1455-63. doi: 10.1182/blood-2013-03-491506. Epub 2013 Jun 14.

PMID:
23770776
21.

Development of orally active inhibitors of protein and cellular fucosylation.

Okeley NM, Alley SC, Anderson ME, Boursalian TE, Burke PJ, Emmerton KM, Jeffrey SC, Klussman K, Law CL, Sussman D, Toki BE, Westendorf L, Zeng W, Zhang X, Benjamin DR, Senter PD.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5404-9. doi: 10.1073/pnas.1222263110. Epub 2013 Mar 14.

22.

Antibody-drug conjugates in cancer therapy.

Sievers EL, Senter PD.

Annu Rev Med. 2013;64:15-29. doi: 10.1146/annurev-med-050311-201823. Epub 2012 Oct 3. Review.

PMID:
23043493
23.

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Senter PD, Sievers EL.

Nat Biotechnol. 2012 Jul 10;30(7):631-7. doi: 10.1038/nbt.2289.

PMID:
22781692
24.

Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues.

Lyon RP, Meyer DL, Setter JR, Senter PD.

Methods Enzymol. 2012;502:123-38. doi: 10.1016/B978-0-12-416039-2.00006-9.

PMID:
22208984
25.

Meeting report: International Symposium on Intelligent Drug Delivery Systems, 2010.

Byun Y, Oh YK, Senter PD, Song SC.

Mol Pharm. 2010 Dec 6;7(6):2310-1. doi: 10.1021/mp1002812. Epub 2010 Oct 6. No abstract available.

PMID:
20925378
26.

Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents.

Jeffrey SC, De Brabander J, Miyamoto J, Senter PD.

ACS Med Chem Lett. 2010 Jun 14;1(6):277-80. doi: 10.1021/ml100039h. eCollection 2010 Sep 9.

27.

Antibody-drug conjugates: targeted drug delivery for cancer.

Alley SC, Okeley NM, Senter PD.

Curr Opin Chem Biol. 2010 Aug;14(4):529-37. doi: 10.1016/j.cbpa.2010.06.170. Epub 2010 Jul 17. Review.

PMID:
20643572
28.

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC.

Clin Cancer Res. 2010 Feb 1;16(3):888-97. doi: 10.1158/1078-0432.CCR-09-2069. Epub 2010 Jan 19. Erratum in: Clin Cancer Res. 2011 Aug 15;17(16):5524.

29.

Antibody drug-conjugates targeting the tumor vasculature: Current and future developments.

Gerber HP, Senter PD, Grewal IS.

MAbs. 2009 May-Jun;1(3):247-53. Review.

30.

Intelligent drug delivery systems.

Oh YK, Senter PD, Song SC.

Bioconjug Chem. 2009 Oct 21;20(10):1813-5. doi: 10.1021/bc900260x. Epub 2009 Sep 3. No abstract available.

PMID:
19728697
31.

The pharmacologic basis for antibody-auristatin conjugate activity.

Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, Benjamin DR.

J Pharmacol Exp Ther. 2009 Sep;330(3):932-8. doi: 10.1124/jpet.109.155549. Epub 2009 Jun 4.

PMID:
19498104
32.

Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.

Burke PJ, Senter PD, Meyer DW, Miyamoto JB, Anderson M, Toki BE, Manikumar G, Wani MC, Kroll DJ, Jeffrey SC.

Bioconjug Chem. 2009 Jun;20(6):1242-50. doi: 10.1021/bc9001097.

PMID:
19469529
33.

Meeting report: International Symposium on Intelligent Drug Delivery Systems South Korea, 2008.

Oh YK, Senter PD, Song SC.

Mol Pharm. 2008 Nov-Dec;5(6):1020-2. doi: 10.1021/mp800162x. No abstract available.

PMID:
19434853
34.

Potent antibody drug conjugates for cancer therapy.

Senter PD.

Curr Opin Chem Biol. 2009 Jun;13(3):235-44. doi: 10.1016/j.cbpa.2009.03.023. Epub 2009 May 4. Review.

PMID:
19414278
35.

Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.

Burke PJ, Toki BE, Meyer DW, Miyamoto JB, Kissler KM, Anderson M, Senter PD, Jeffrey SC.

Bioorg Med Chem Lett. 2009 May 15;19(10):2650-3. doi: 10.1016/j.bmcl.2009.03.145. Epub 2009 Apr 5.

PMID:
19386499
36.

Meeting report: drug carriers in medicine and biology.

Senter PD, Scheinberg DA.

Mol Pharm. 2009 Jan-Feb;6(1):82-5. doi: 10.1021/mp800258g. No abstract available.

37.

A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.

Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D, Senter PD, Gao C, Wu H, Kinch M, Coats S, Kiener PA, Tice DA.

Cancer Res. 2008 Nov 15;68(22):9367-74. doi: 10.1158/0008-5472.CAN-08-1933.

38.

Novel peptide linkers for highly potent antibody-auristatin conjugate.

Doronina SO, Bovee TD, Meyer DW, Miyamoto JB, Anderson ME, Morris-Tilden CA, Senter PD.

Bioconjug Chem. 2008 Oct;19(10):1960-3. doi: 10.1021/bc800289a. Epub 2008 Sep 20.

PMID:
18803412
39.

Antibody-drug conjugates for cancer therapy.

Carter PJ, Senter PD.

Cancer J. 2008 May-Jun;14(3):154-69. doi: 10.1097/PPO.0b013e318172d704. Review.

PMID:
18536555
40.

Contribution of linker stability to the activities of anticancer immunoconjugates.

Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, Senter PD.

Bioconjug Chem. 2008 Mar;19(3):759-65. doi: 10.1021/bc7004329. Epub 2008 Mar 4.

PMID:
18314937
41.

Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative.

Temming K, Meyer DL, Zabinski R, Senter PD, Poelstra K, Molema G, Kok RJ.

Mol Pharm. 2007 Sep-Oct;4(5):686-94. Epub 2007 Aug 8.

PMID:
17683157
42.

Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.

Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, MacDougall JR, Arrol S, Zhong H, Gerwien RW, Hahne WF, Senter PD, Jeffers ME, Lichenstein HS, LaRochelle WJ.

Cancer Chemother Pharmacol. 2007 Aug;60(3):423-35. Epub 2007 Jun 1.

PMID:
17541593
43.

Chemotherapy delivery issues in central nervous system malignancy: a reality check.

Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM, Neuwelt EA.

J Clin Oncol. 2007 Jun 1;25(16):2295-305. Review.

PMID:
17538176
44.

Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker.

Jeffrey SC, Nguyen MT, Moser RF, Meyer DL, Miyamoto JB, Senter PD.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2278-80. Epub 2007 Jan 27.

PMID:
17293111
45.

Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.

Jeffrey SC, Andreyka JB, Bernhardt SX, Kissler KM, Kline T, Lenox JS, Moser RF, Nguyen MT, Okeley NM, Stone IJ, Zhang X, Senter PD.

Bioconjug Chem. 2006 May-Jun;17(3):831-40.

PMID:
16704224
46.

Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.

Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, Olson WC.

Clin Cancer Res. 2006 Apr 15;12(8):2591-6.

47.

Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, Liu A, Ueda R, Hodges D, Escandon E, Chen T, Kanavarioti T, Babé L, Senter PD, Fox JA, Schellenberger V.

Bioconjug Chem. 2006 Mar-Apr;17(2):410-8.

PMID:
16536473
48.

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ.

Clin Cancer Res. 2006 Feb 15;12(4):1373-82.

49.

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF.

Cancer Res. 2006 Feb 15;66(4):2328-37.

50.

Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.

Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law CL, Wahl AF.

J Biol Chem. 2006 Apr 14;281(15):10540-7. Epub 2006 Feb 16.

Supplemental Content

Loading ...
Support Center